Scientific program


Program at a Glance can be found here

Outline of the Scientific Program can be downloaded here


S01 Alcoholic fatty liver: Pathology and screening strategies
Chairs: Sebastian Mueller, Germany, Claus Hellerbrand, Germany
Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease. Claus Hellerbrand, Germany
Controlled attenuation parameter- a novel way to measure fatty liver. Magali Sasso, France
CAP multicenter Controlled attenuation parameter accurately diagnoses hepatic steatosis in patients with alcoholic liver disease. Maja Thiele, Denmark
Delayed resolution of liver stiffness and steatosis after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M. Sebastian Mueller, Germany

S02 Acute and chronic effects of ethanol on ligand-gated ion channels
Chairs: Luis G. Aguayo, Chile, Mia Ericson Sweden
Modulation of ligand-gated ion channels by ethanol. Robert J Harvey, UK
Role of glycine receptors in ethanol consumption behavior. Mia Ericson, Sweden
Persistent neuroplasticity in VTA DA neurons induced by alcohol and GABAergic drugs. Esa Korpi, Finland
The presence of glycine receptors in different brain regions can explain the different effects of ethanol. Luis G. Aguayo, Chile

S03 Investigation of vulnerability to addictive behavior in animal models of alcohol use disorder
Chairs: Mickael Naassila, France, David Belin, UK
Interactions between microbiota and alcohol-related behaviors. José-Antonio Lopez-Moreno, Spain
Social play as a factor for risk or resilience to loss of control over alcohol seeking rats. Heidi Lesscher, Netherlands
Recent findings on the heterogeneous addictive phenotype in alcohol-preferring rats. David Belin, UK
Vulnerability to develop excessive alcohol intake in the post-dependent state model of voluntary binge drinking rats. Mickael Naassila, France

S04 Role of iron in alcoholic liver disease: Molecular insights and prognostic aspects
Chairs: Sebastian Mueller, Germany, Carolin Lackner, Austria
Histology of iron overload in alcoholic liver disease: Are there prognostic implications? Carolin Lackner, Austria
Iron parameters determine the mortality in alcoholic liver disease. Pavel Strnad, Germany
Role of hypoxia as a cofactor in iron accumulation. Andreas Geier, Germany
Independent and additive induction of hepcidin by hypoxia and peroxide: Evidence for NOX4-mediated iron signaling. Ines Silva, Portugal
Masked-hemolysis as novel cause of hepatic iron overload in ALD. Sebastian Mueller, Germany

S05 Drinking to cope or coping not to drink – managing emotions in alcohol dependence
Chairs: Marcin Wojnar ,Poland, Kirk J. Brower, USA
Inter- and intrapersonal emotional processes in treated alcohol-dependent patients and non-addicted healthy individuals Maciej Kopera, Poland
Physician drinking and depression Kirk J. Brower, USA
Alcohol dependence in psychopathy Aleksandra Krasowska, Poland
Emotion regulation and impulsivity in alcohol-dependent patients Andrzej Jakubczyk, Poland

S06 Modifiers of progression of alcoholic liver disease
Chairs: Claus Hellerbrand, Germany, Felix Stickel, Switzerland
Effect of Iso-alpha-acids, bitter acids in beer, on acute alcohol induced liver injury. Ina Bergheim, Austria
Influence of hepatic preinjury on development of alcoholic liver disease. Steven Dooley, Germany
Effects of the hop flavonoid Xanthohumol on alcohol induced hepatic steatosis, inflammation and fibrosis. Claus Hellerbrand, Germany
Cannabinoid receptors modulate alcohol-induced liver injury. Eleonora Patsenker, Switzerland

S07 Treatment of alcohol dependence with agonistic substances
Chairs: Albrecht Ulmer, Germany, Icro Maremmani, Italy
Established and future therapies in chronic alcohol dependence. Henriette Walter, Austria
Documented experience with Dihydrocodeine, Buprenorphine, Baclofen and Clomethiazole. Albrecht Ulmer, Germany
Treatment with GHB for Heroin addicts with alcohol dependence. Clinical study results. Icro Maremmani, Italy

S08 Clinically relevant research in subgroups of alcoholism
Chairs: Roberta Ward, UK and Belgium, Henriette Walter, Austria
Towards personalized treatments for alcohol use disorder: a focus on alpha-1 blockade. Carolina L. Haass-Koffler, USA
Temperament and motivation in subgroups of alcoholism. Samuel Pombo, Portugal
GLIA: M1 and M2 in subtypes of alcoholism. Roberta Ward, UK and Belgium
Pharmacotherapy in LAT. Henriette Walter, Austria
Discussant: Otto Lesch, Austria

S09 Role of Nutrition in Alcoholic Liver Disease
Chairs: Irina A. Kirpich, USA, Craig J. McClain, USA
Dietary Linoleic Acid and its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Pro-inflammatory Response. Irina A. Kirpich, USA
Role of fat/carbohydrate ratio and dietary fat type in development of alcoholic pathology. Martin J.J. Ronis, USA
Betaine: A Promising Therapeutic in the Treatment of Alcohol-Induced Liver Injury. Kusum Kharbanda, USA
Zinc deficiency mediates alcohol-induced hepatocyte apoptosis via perturbing mitochondrial electron transport chain. Zhanxiang Zhou, USA
Summary and Discussion. Nutrition and Alcohol-induced Multiorgan Pathology: Clinical Aspects. Craig J. McClain, USA

S10 Why do repeated alcohol detoxifications matter?
Chairs: Christos Kouimtsidis, UK, Theodora Duka, UK
Cognitive and psychological impact of alcohol detoxifications. Theodora Duka, UK
Chronic ethanol exposure and withdrawal upregulates TSPO-A marker of neuroinflammation and mGluR5 binding: correlation with memory and motor impairment. Alexis Bailey, UK
Clinical implications and interventions to reduce the risk of unsuccessful alcohol detoxifications. Christos Kouimtsidis, UK

S11 Novel G protein-coupled receptors as potential targets for treating alcoholism
Chair: Esa Korpi, Finland
Introduction: Beyond the opioid receptor antagonists. Esa Korpi, Finland
Novel findings on Nociceptin receptor system as a treatment target for alcoholism. Roberto Ciccocioppo, Italy
Targeting the dopamine D3 receptor for the treatment of alcohol addiction. Gian Marco Leggio, Italy
Amylin receptors and alcohol-related behaviors. Elisabet Jerlhag, Sweden
Oxytocin system and alcohol reward: from rodents to man. Rainer Spanagel, Germany

S12 Possibilities and pitfalls in mutual help for alcohol problems
Chairs: Jonathan Chick, UK, David Best, UK
Learning resilience: exploring recovery in a sample of adherents of the 12 step groups. Claire Hiernaux, France
Can mutual aid groups stimulate social reintegration: an empirical study. David Best, UK
Postponing relapse, use of medications and outcomes in mutual aid groups in France. Bertrand Nalpas, France
Barriers to professional’s usage of mutual aid groups. Jonathan Chick, UK.
Measuring the value of on-line mutual aid. Julia Sinclair, UK

S13 Challenges in the treatment of alcoholic liver disease
(Symposium organized by the Hellenic Association for the Study of the Liver)
Chairs: Evangelos Akriviades, Greece, George Dalekos, Greece
Treatment strategies and optimal therapeutic interventions in acute alcoholic steatohepatitis. Αlexandra Alexopoulou, Greece
Current views on pentoxyphylline issue for acute alcoholic steatohepatitis. Dimitrios Samonakis, Greece
Succeeding alcohol abstinence: A hard issue? Mairi Koulentaki, Greece
Liver transplantation in alcoholic liver disease: Pros & Cons. Emmanouil Sinakos, Greece

S14 New approaches for understanding alcohol use disorders and potential new treatments (ESBRA-LASBRA Joint Symposium)
Chairs: Rosana Camarini, Brazil, Mickael Naassila, France
The role of the oxytocin system on ethanol conditioned place preference. Alexis Bailey, UK and Rosana Camarini, Brazil
Pharmacological activation of the aldehyde dehydrogenase: a new experimental approach for reducing ethanol consumption. Mario Rivera-Meza, Chile
N-acetyl cysteine in a new model of voluntary binge drinking in rats. Mickael Naassila, France

S15 New insights into adolescent binge drinking: Preclinical and clinical studies
Chairs: Consuelo Guerri, Spain, Rosana Camarini, Brasil
Neuroinflammation and epigenetic processes after only two binges of ethanol in young adult rats. Oliver Pierrefiche, France
Sex differences in peripheral and brain inflammation in adolescents with binge drinking: Preclinical and clinical studies. Consuelo Guerri, Spain
Episodic memory in young binge drinkers: a neuropsychological approach. Carina Carbia, Spain
Effects of environmental enrichment upon ethanol-induced conditional place preference and BDNF levels in adolescent and adult mice. Rosana Camarini, Brazil

S16 Alcoholic Fatty Liver Disease: Use of Animal and Cell Models for Identification of Potential Novel Therapeutic Targets and Implications of Alcohol-therapeutic Interactions
Chairs: Carol A. Casey, USA, Laura E Nagy, USA
miR181b-3p and its Target Importin α5 Regulate TLR4 Signaling in Kupffer Cells and Liver Injury in Mice in Response to Ethanol. Laura E Nagy, USA
MitoNEET Deficiency Stimulates Endocrine Adiponectin-FGF15/19 Signaling and Alleviates Alcoholic Steatohepatitis in Mice.. Min You, USA
Ethanol-induced Disorganization of Golgi Apparatus: Role of Defective Rab3D Function. Carol A. Casey, USA
Alcohol-therapeutic Interactions: Role in Liver Damage. Manuela Neuman, Canada

S17 Alcohol use disorders in the General Hospital
Chairs: Ioannis Diakogiannis, Greece, Panagiotis Panagiotidis, Greece
Management of alcoholic patients in the emergency department: Physical and psychiatric problems. Dimitra Tsaklakidou, Greece
Screening and Brief Interventions for Alcohol Use Disorders in a General Hospital setting. Panagiotis Panagiotidis, Greece
Liaison services for Alcohol Use Disorders in the General Hospital. Konstantinos Randis, Greece
Group therapy for Alcohol Use Disorders in a General Hospital setting. Ioannis Diakogiannis, Greece

S18 Joint EASL-ESBRA symposium
New molecular insight leads to new therapeutic concepts
Chairs: Helena Cortez-Pinto (EASL), Felix Stickel (ESBRA)
mRNA in alcoholic hepatitis – marker or target, or both? Delia Blaya/Pau Sancho-Bru, Spain
Alcohol withdrawal and hepatic encephalopathy in cirrhotics – a therapeutic dilemma. Marsha Y. Morgan, UK
How to address alcohol dependence in patients with alcoholic liver disease safely. Marcin Wojnar, Poland
Applying genetic information on HCC surveillance strategies – Are we yet there? Luca Valenti, Italy

S19 Alcohol use disorders in Greece: Clinical and treatment issues
Chairs: Thomas Paparrigopoulos, Greece, Dimos Fotopoulos, Greece
Alcohol use disorders and co-occurring psychopathology: Clinical issues and strategies. Eleftherios Mellos, Greece
Alcohol treatment modalities: the Greek experience – the “Athina” Unit paradigm. Dimitrios Panteleakis, Greece
Alcohology Outpatient Clinic in a University Hospital. Aspects of an interdisciplinary approach. Evangelos Grinakis, Greece
Treatment of alcohol use disorders in an inpatient setting: Clinical issues and management. Thomas Paparrigopoulos, Greece
Priorities and concerns on alcohol use in Europe and Greece. Dimos Fotopoulos, Greece

S20 Alcohol potentiates the pathogenesis of viral infections
Chairs: Kusum K. Kharbanda, USA, Natalia A. Osna USA
Alcohol potentiates viral hepatitis progression: role of apoptotic bodies. Natalia A. Osna, USA
Alcohol increase circulating exosomes and exosomes from hepatitis C infected patients transmit HCV infection. Gyongyi Szabo, USA
Chronic hazardous alcohol use: role in HIV-associated metabolic comorbidities. Patricia E. Molina, USA
Alcoholic liver disease and hepatitis C. Sebastian Mueller, Germany
Discussant: Samir Zakhari, USA

S21 Comorbidities of alcohol dependence
JMSAAS/ESBRA joint symposium
Chairs: Toshi Saito, Japan, Helmut K. Seitz, Germany
The role of Class III Alcohol Dehydrogenase (ADH3) in alcohol-related disorder on liver and bone. Takahisa Okuda, Japan
Survey of the relationship between alcohol -related cognitive dysfunction and cerebral blood flow. Tomohiro Shirasaka, Japan
Comorbidities of alcoholics with homozygous for the aldehyde dehydrogenase 2*2 gene allele. Fumihiko Ueno, Japan
Alcohol misuse in combination with drug of use; a deadly combination. Manuela Neuman, Canada
Hypoxia induced hepcidine: role of stat3 in the liver. Ines Silva, Germany

Chairs: Tomas Zima, Czech Republic, Iannis Mouzas, Greece
Speakers to be announced

S23 Alcohol and cancer
Chairs: Vasilis Vasiliou, USA, Helmut K. Seitz, Germany
Alcohol and cancer mechanisms: an update 2017. Samir Zakhari, USA
Alcohol and cancer: An epidemiology update 2017. Carlo La Vecchia, Italy
Molecular mechanisms in alcohol-related colorectal cancer. Vasilis Vasiliou, USA
Alcohol and fat: double whammy for liver injury and cancer. Devanshi Seth, Australia
The role of Cytochrome P450 2E1 (CYP2E1) in alcohol-mediated cancer: translational studies. Helmut K. Seitz, Germany

S24 Neuroimaging Consortia in Alcohol Research
Chairs: Rainer Spanagel, Germany, Mickael Naassila, France
The ICCAM platform: To investigate the neuropharmacology of brain processes relevant to addiction. Karen Ersche, England
The SyBil-AA project: Modeling and validating disease state networks in human and animal brains. Wolfgang Sommer, Germany
IMAGEN: Determinants of early alcohol use in healthy adolescents. Frauke Nees, Germany
National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA). Determinants of problematic alcohol use on the developing adolescent brain. Bonnie J. Nagel, USA

Plenary Lectures
PL1 Ethanol’s interaction with brain dopamine systems provides clues for new treatments of alcoholism. Bo Söderpalm, Sweden
PL2 Pharmacological treatment of alcoholic patients: a focus on GABAB-ergic drugs. Giovanni Addolorato, Italy
PL3 Alcohol and Cancer: From epidemiology to genetic susceptibility and animal models. Vasilis Vasiliou, USA
PL4 Alcohol misuse in special populations; learning disabilities and people with traumatic brain injury.. Christos Kouimtsidis, UK
PL5 Subgroups of addiction: From basic research to therapy. Otto Lesch, Austria
PL6 Fetal Alcohol Spectrum Disorders (FASD). An overview. Edward P. Riley, USA
PL7 Alcohol-related liver disease and its neurological co morbidities–is it all in the genes. Marsha Y Morgan, UK
CHARLES LIEBER MEMORIAL LECTURE Alcohol Intake: From Initiation to Relapse Binge-drinking. Mechanisms and Translational Opportunities. Yedi Israel, Chile

WS 1 Human error, medical error and how they are built. Anthony Kogevinas, Greece, NurdanTözün, Turkey
WS 2 Lesch Typology: How to use it in daily practice. Otto Lesch, Austria
WS 3 Benefits of hypnotherapy against craving? Henriette Walter, Austria
WS 4 Cognitive behavioral treatment in alcohol use disorders. A user guide. Christos Kouimtsidis, UK